Multiple marker evaluation in prostatic cancer using prostatic specific antigen, gamma-seminoprotein and prostatic...

Area of Science:

• Urology
• Oncology
• Biomarker Research

Background:

• Prostate cancer diagnosis and monitoring rely on accurate biomarkers.
• Existing markers like prostatic acid phosphatase (PAP) have limitations in sensitivity and specificity.

Purpose of the Study:

• To evaluate the diagnostic and prognostic value of serum prostatic specific antigen (PA), gamma-seminoprotein (gamma-Sm), and prostatic acid phosphatase (PAP) in prostate cancer patients.
• To compare the sensitivity and specificity of these markers individually and in combination.

Main Methods:

• Serum levels of PA, gamma-Sm, and PAP were measured in 141 prostate cancer patients (121 newly diagnosed) and 131 patients with benign prostatic hypertrophy.
• Marker detectability, sensitivity, and specificity were assessed across different disease stages.
• Serial marker levels were monitored during a 1-53 month follow-up to detect disease progression.

Main Results:

• In untreated patients, PA, gamma-Sm, and PAP were detectable in 77%, 71%, and 67% respectively.
• PA exhibited equal or greater sensitivity than gamma-Sm and PAP across all stages.
• Combined marker analysis increased sensitivity to 86% in all stages and 74% in localized disease, but did not improve specificity.
• Gamma-Sm showed higher sensitivity for early detection of disease progression during follow-up.

Conclusions:

• Serum PA and gamma-Sm are reliable biomarkers for the detection and monitoring of prostate cancer.
• PA demonstrates strong sensitivity across all disease stages.
• Gamma-Sm shows potential for early detection of disease progression, aiding in patient management.